Corbus Pharmaceuticals Investigated by Block & Leviton LLP For Violations of Federal Securities Laws
February 28, 2019 13:49 ET
|
Block & Leviton LLP
BOSTON, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors nationwide, is investigating whether Corbus Pharmaceuticals...
Corbus Pharmaceuticals Presents Lenabasum Long-Term Open-Label Clinical Data Showing Maintenance of Favorable Safety Profile and Further Improvement in Multiple Efficacy Endpoints in Systemic Sclerosis and Dermatomyositis Phase 2 Studies
October 22, 2018 08:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Lenabasum is a first-in-class novel, synthetic oral cannabinoid designed to treat rare, serious autoimmune diseasesFavorable safety and tolerability profiles maintained with long-term chronic...